---
title: 'Life Sciences Daily Summary: What Happened on November 12, 2026'
headline: Blackstone to fund up to $1.5 billion of Pfizer’s obesity-drug development
description: Neurosterix raised $105 million for a schizophrenia drug. Lilly added
  two medicines to Hims & Hers, and the FDA ordered an eye-risk warning across GLP-1
  labels.
url: https://thebench.bio/news/summaries/2026-11-12
topic: all
date: '2026-11-12'
covers:
- '2026-11-12'
date_published: '2026-11-12T12:04:25Z'
date_modified: '2026-11-13T00:05:26Z'
tags:
- Funding
- Industry
- Software
sources: 6
publisher: TheBench.Bio
---

# Life Sciences Daily Summary: What Happened on November 12, 2026

**Blackstone to fund up to $1.5 billion of Pfizer’s obesity-drug development**

Neurosterix raised $105 million for a schizophrenia drug. Lilly added two medicines to Hims & Hers, and the FDA ordered an eye-risk warning across GLP-1 labels.

## Today in brief

Blackstone Life Sciences will cover up to $1.5 billion of Pfizer’s berobenatide development costs through 2028, with possible payments tied to approval and sales milestones. [1] [2] Neurosterix raised $105 million to advance its schizophrenia candidate NTX-253 toward Phase 2 after completing Phase 1 studies. [3] Lilly will offer Zepbound and Foundayo through Hims & Hers at Lilly’s self-pay prices for eligible patients with prescriptions. [4] The FDA directed makers of all GLP-1 receptor agonists to add a warning about a rare risk of sudden vision loss. [4] Biopharma layoffs affected 43% more workers in October than in October 2025, while reported cuts through October remained below 2025’s total. [5]

## Blackstone will share Pfizer’s berobenatide development costs

Blackstone Life Sciences agreed to fund up to $1.5 billion of Pfizer’s berobenatide development costs through 2028. [1] [2] The investigational monthly GLP-1 drug is being studied for chronic weight management. Pfizer retains control of development decisions. [1] [2]

Blackstone receives no ownership or drug rights, but may receive payments if berobenatide gains US approval for chronic weight management and meets specified sales goals. [1] [2] In a Phase 2b trial, monthly 4.8-milligram dosing produced up to 12.3% greater weight loss than placebo at 28 weeks. [2] [6] Pfizer has 10 berobenatide Phase 3 studies underway or planned. [2] [6]

## Neurosterix raises $105 million for its schizophrenia program

Neurosterix raised $105 million in a Series B round led by RTW Investments to advance NTX-253 toward Phase 2. [3] The company said it completed Phase 1 studies in healthy volunteers and people with stable schizophrenia in October. [3]

NTX-253 is an oral positive allosteric modulator of the muscarinic M4 receptor, designed to amplify the receptor’s response to acetylcholine. [3] Neurosterix said Phase 1 pharmacokinetic data support once-daily dosing. The drug’s clinical efficacy has not yet been demonstrated. [3]

## Lilly medicines will be available through Hims & Hers

Lilly and Hims & Hers agreed to make Zepbound and Foundayo available through the telehealth company’s platform at Lilly’s self-pay prices. [4] The offer is for eligible patients who receive prescriptions from licensed providers. [4]

Novo Nordisk made Wegovy and Ozempic available through Hims & Hers in March. That deal also ended a patent lawsuit against the telehealth company. [4] Hims & Hers says it has not sold compounded versions of Lilly’s GLP-1 medicines and has pledged not to do so. [4]

## FDA orders eye-risk warning across GLP-1 drug labels

The FDA directed manufacturers of all GLP-1 receptor agonists to add a warning about a possible increased risk of nonarteritic anterior ischemic optic neuropathy, or NAION. [4] NAION is an uncommon condition that can cause sudden, painless vision loss in one eye. [4]

The FDA’s review followed a July 2024 observational study. The agency found that NAION remained rare in the clinical and real-world evidence it assessed. [4] The FDA is asking prescribers to tell patients to report sudden vision changes promptly. [4]

## October layoffs rose year over year, but 2026 cuts remain lower

Fifteen biopharma companies made or planned layoffs in October. The number of affected workers was 43% higher than in October 2025. [5] October was the first month of 2026 in which both the number of employers reporting or planning cuts and the affected-worker total exceeded the same month a year earlier. [5]

Through October, 99 companies had cut or planned cuts affecting 19,538 people, compared with 200 companies and 43,242 workers in all of 2025. [5] Artiva Biotherapeutics said it would cut 94% of its workforce and stop developing AlloNK after two patient deaths and concerns about the duration of clinical responses. [5] Caribou Biosciences attributed its cuts and decision to stop advancing its clinical-stage pipeline to a financing freeze in the CAR T field. [5]

## The day in numbers

- **Up to $1.5 billion**: Maximum Blackstone funding for Pfizer’s berobenatide development through 2028. [1] [2]
- **12.3%**: Maximum placebo-adjusted weight loss reported with monthly berobenatide at 28 weeks in Phase 2b. [2] [6]
- **$105 million**: Neurosterix’s Series B financing to advance its schizophrenia candidate. [3]
- **19,538**: People affected by reported or planned biopharma layoffs through October 2026. [5]

## Sources

1. [Pfizer and Blackstone Sign Co-Funding Deal for berobenatide](<https://www.pharmexec.com/view/pfizer-blackstone-sign-co-funding-deal-berobenatide>), Pharmaceutical Executive, 2026-11-12
2. [Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development](<https://www.biopharminternational.com/view/blackstone-to-provide-pfizer-up-to-1-5-billion-for-monthly-glp-1-berobenatide-development>), BioPharm International, 2026-11-12
3. [Addex spinout Neurosterix raises $105M to advance schizophrenia drug into Phase 2](<https://european-biotechnology.com/latest-news/addex-spinout-neurosterix-raises-105m-to-advance-schizophrenia-drug-into-phase-2/>), European Biotechnology, 2026-11-12
4. [Pharma Pulse: Lilly and Hims & Hers Team Up, Swisslog Expands Tenutō Cold Storage](<https://www.pharmaceuticalcommerce.com/view/pharma-pulse-lilly-and-hims-hers-team-up-swisslog-expands-tenut-cold-storage>), Pharmaceutical Commerce, 2026-11-12
5. [Biopharma layoffs rise YOY in October but sharply trend down for 2026](<https://www.biospace.com/job-trends/biopharma-layoffs-rise-yoy-in-october-but-sharply-trend-down-for-2026>), BioSpace, 2026-11-12
6. [The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA](<https://www.biopharminternational.com/view/the-biopharm-brief-an-ai-designed-multibody-adc-enters-the-clinic-blackstone-backs-pfizer-s-monthly-glp-1-and-engene-readies-a-bladder-cancer-bla>), BioPharm International, 2026-11-12

---

TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://www.pharmexec.com/view/pfizer-blackstone-sign-co-funding-deal-berobenatide>
[2]: <https://www.biopharminternational.com/view/blackstone-to-provide-pfizer-up-to-1-5-billion-for-monthly-glp-1-berobenatide-development>
[3]: <https://european-biotechnology.com/latest-news/addex-spinout-neurosterix-raises-105m-to-advance-schizophrenia-drug-into-phase-2/>
[4]: <https://www.pharmaceuticalcommerce.com/view/pharma-pulse-lilly-and-hims-hers-team-up-swisslog-expands-tenut-cold-storage>
[5]: <https://www.biospace.com/job-trends/biopharma-layoffs-rise-yoy-in-october-but-sharply-trend-down-for-2026>
[6]: <https://www.biopharminternational.com/view/the-biopharm-brief-an-ai-designed-multibody-adc-enters-the-clinic-blackstone-backs-pfizer-s-monthly-glp-1-and-engene-readies-a-bladder-cancer-bla>
